Jefferies initiated coverage of Nuvalent with a Buy rating and $97 price target. The company leverages strong expertise in structure-based chemistry and deep understanding of unmet pts needs to develop potentially “best-in-class” small molecule targeted cancer therapy, the analyst tells investors in a research note. The firm says the company’s two candidates could generate $1.7B and $2.6B in adjusted peak sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent presents data on NVL-330, zidesamtinib at AACR
- Crocs initiated, Bill downgraded: Wall Street’s top analyst calls
- Leerink more bullish on Nuvalent, upgrades to Outperform
- Nuvalent upgraded to Outperform from Market Perform at Leerink
- Nuvation Bio upgraded to Buy at Jefferies following acquisition of AnHeart
